- Overview
- Properties
- Genetics
- Related Genes
- Pathways
- Related Drugs
- Related Diseases
- Datasets
- Downloads/LinkOuts
Overview
| Generic Names: | 5,5-Dwufenylohydantoina; 5,5-diphenylhydantoin; DPH; Difenilhidantoina [Spanish]; Dihydantoin; Diphenylan Sodium; Diphenylhydantoin; Diphenylhydantoine [French]; Diphenylhydatanoin; Fenitoina [INN-Spanish]; Phenytoin Sodium; Phenytoine; Phenytoine [INN-French]; Phenytoinum [INN-Latin] |
|---|---|
| Trade Names: | Aleviatin; Antisacer; Auranile; Causoin; Citrullamon; Citrulliamon; Comital; Comitoina; Convul; Danten; Dantinal; Dantoinal; Dantoinal klinos; Dantoine; Denyl; Di-Hydan; Di-Lan; Di-Phetine; Didan TDC 250; Difenilhidantoina; Difenin; Difetoin; Difhydan; Dihycon; Dilabid; Dilantin; Dilantin acid; Dilantin-125; Dilantine; Dillantin; Dintoin; Dintoina; Diphantoin; Diphedal; Diphedan; Diphenat; Diphenin; Diphenine; Diphentoin; Diphentyn; Diphenylan; Ditoinate; Ekko; Elepsindon; Enkelfel; Epamin; Epanutin; Epasmir 5; Epdantoin Simple; Epdantoine simple; Epelin; Epifenyl; Epihydan; Epilan; Epilan D; Epilan-D; Epilantin; Epinat; Epised; Eptal; Eptoin; Fenantoin; Fenidantoin s; Fentoin; Fenylepsin; Fenytoin Dak; Fenytoine; Gerot-epilan-D; Hidan; Hidantal; Hidantilo; Hidantina; Hidantina senosian; Hidantina vitoria; Hidantomin; Hindatal; Hydantal; Hydantin; Hydantoin; Hydantoinal; Hydantol; Ictalis simple; Idantoil; Idantoin; Iphenylhydantoin; Kessodanten; Labopal; Lehydan; Lepitoin; Lepsin; Mesantoin; Minetoin; Neos-Hidantoina; Neosidantoina; Novantoina; Novophenytoin; Om hidantoina simple; Om-Hydantoine; Oxylan; Phanantin; Phanatine; Phenatine; Phenatoine; Phenhydan; Phenhydanin; Phenitoin; Phentoin; Phentytoin; Phenytex; Phenytoin AWD; Phenytoin-Gerot; Prompt Phenytoin Sodium; Ritmenal; Saceril; Sanepil; Silantin; Sinergina; Sodanthon; Sodantoin; Sodanton; Solantin; Solantoin; Solantyl; Sylantoic; TOIN; Tacosal; Thilophenyl; Toin unicelles; Zentronal; Zentropil |
| Brand Mixtures: | Dilantin W Phenobarbital 15mg (Phenobarbital + Phenytoin Sodium); Dilantin W Phenobarbital 30mg Cap (Phenobarbital + Phenytoin Sodium) |
| PharmGKB Accession Id: | PA450947 |
Description
An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs. PubChem (source: Drug Bank)
Indication
For the control of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery. (source: Drug Bank)
ATC Therapeutic Category
- N03AB:Hydantoin derivatives
Pharmacology, Interactions, and Contraindications
Mechanism Of Action
Phenytoin acts on sodium channels on the neuronal cell membrane, limiting the spread of seizure activity and reducing seizure propagation. By promoting sodium efflux from neurons, phenytoin tends to stabilize the threshold against hyperexcitability caused by excessive stimulation or environmental changes capable of reducing membrane sodium gradient. This includes the reduction of post-tetanic potentiation at synapses. Loss of post-tetanic potentiation prevents cortical seizure foci from detonating adjacent cortical areas. (source: Drug Bank)
Pharmacology
Phenytoin is an antiepileptic drug which can be useful in the treatment of epilepsy. The primary site of action appears to be the motor cortex where spread of seizure activity is inhibited. Phenytoin reduces the maximal activity of brain stem centers responsible for the tonic phase of tonic-clonic (grand mal) seizures. Phenytoin acts to damp the unwanted, runaway brain activity seen in seizure by reducing electrical conductance among brain cells. It lacks the sedation effects associated with phenobarbital. There are some indications that phenytoin has other effects, including anxiety control and mood stabilization, although it has never been approved for those purposes by the FDA. (source: Drug Bank)
Food Interactions
Avoid alcohol.
Do not take calcium, aluminum, magnesium or Iron supplements within 2 hours of taking this medication.
Take with food to increase bioavailability and reduce irritation.
(source:
Drug Bank)
Absorption, Distribution, Metabolism, Elimination & Toxicity
Biotransformation
Primarily hepatic (source: Drug Bank)
Protein Binding
Highly protein bound (source: Drug Bank)
Absorption
Bioavailability 70-100% oral, 24.4% for rectal and intravenous administration. Rapid rate of absorption with peak blood concentration expected in 1½ to 3 hours. (source: Drug Bank)
Toxicity
Oral, mouse: LD<sub>50</sub> = 150 mg/kg; Oral, rat: LD<sub>50</sub> = 1635 mg/kg. Symptoms of overdose include coma, difficulty in pronouncing words correctly, involuntary eye movement, lack of muscle coordination, low blood pressure, nausea, sluggishness, slurred speech, tremors, and vomiting. (source: Drug Bank)
Isomeric SMILES Code:
c1ccc(cc1)C2(C(=O)NC(=O)N2)c3ccccc3 (source: Drug Bank)
In-Depth Annotations (
)
-
rs1799853
at chr10:96692037
in
CYP2C9
This variant has been shown to influence warfarin dose as well as affecting the clearance of several other drugs.- Variant Name:
- CYP2C9*2; CYP2C9:144Arg>Cys
- Related Drugs:
- fluvastatin, glipizide, phenytoin, tolbutamide, warfarin
- Evidence:
-
http://www.pharmgkb.org/.../variant.jsp#ImportantVariantInformationforCYP2C9-111
-
rs1057910
at chr10:96731043
in
CYP2C9
This variant has been shown to correlate significantly with warfarin dose as well as affecting the clearance of several other drugs.- Variant Name:
- CYP2C9*3; CYP2C9:359Ile>Leu
- Related Drugs:
- fluvastatin, glipizide, phenytoin, tolbutamide, warfarin
- Evidence:
-
http://www.pharmgkb.org/.../variant.jsp#ImportantVariantInformationforCYP2C9-222
Curated Annotations (
)
-
rs1051740
at chr1:224086256
in
EPHX1
Risk or phenotype-associated allele: T. Phenotype: In a logistic regression model adjusted for history of phenytoin use during the first trimester and maternal epilepsy, the maternal EPHX1 113 H (rs1051740 T/C) allele was associated with craniofacial abnormalities in the child. Study size: 157 pregnancies. Study population/ethnicity: phenytoin use during the first trimester and maternal epilepsy. metric(s): per rare allele OR: 2.43, 95% confidence interval (CI): 1.16-5.10, P=0.02. Type of association: GN.- Variant Name:
- EPHX1: Y113H; 337T>C
- Related Drugs:
- phenytoin
- Related Diseases:
- Craniofacial Abnormalities
- Evidence:
-
PMID:19952982
-
rs2234922
at chr1:224093029
in
EPHX1
Risk or phenotype-associated allele: G. Phenotype: In a logistic regression model adjusted for history of phenytoin use during the first trimester and maternal epilepsy, the maternal EPHX1 139 R (rs2234922A/G) allele was associated with craniofacial abnormalities in the child. Study size: 157 pregnancies. Study population/ethnicity: phenytoin use during the first trimester and maternal epilepsy. metric(s): per rare allele OR: 2.33, 95% CI: 1.09-5.00, P=0.03. Type of association: GN.- Variant Name:
- EPHX1: H139R; 416A>G
- Related Drugs:
- phenytoin
- Related Diseases:
- Craniofacial Abnormalities
- Evidence:
-
PMID:19952982
-
rs2304016
at chr2:165876749
in
SCN2A,
SCN2A2
The A allele of this SNP was associated with resistance to sodium channel-blocking anti-epileptic drugs in a Chinese patient population.- Variant Name:
- SCN2A:IVS7-32A>G
- Related Drugs:
- carbamazepine, lamotrigine, oxcarbazepine, phenytoin, topiramate
- Related Diseases:
- Epilepsy
- Evidence:
-
PMID:18784617
-
rs3812718
at chr2:166617790
in
SCN1A
This SNP is associated with required dose levels of antieptilectic drugs. It affects alternative splicing and hence the proportions of neonate and adult alternative transcripts of SCN1A in adult brain tissue. The effect of the polymorphism appears to be modified by Nova2 expression levels.- Related Drugs:
- carbamazepine, phenytoin
- Evidence:
-
PMID:17436242
-
rs3909184
at chr6:30807363
in
FLOT1
This variant is a tagging SNP for HLA-B*1502, which is associated with severe adverse reactions of carbamazepine. Patients carrying the HLA-B*1502 allele have significant higher risk for severe skin reactions (Stevens Johnson syndrome and toxic epidermal necrolysis) associated with carbamazepine therapy.- Variant Name:
- tagging SNP for HLA-B*1502
- Related Drugs:
- carbamazepine, phenytoin
- Related Diseases:
- Bipolar Disorder, Epidermal Necrolysis, Toxic, Epilepsy, Stevens-Johnson Syndrome
- Evidence:
-
PMID:15057820
PMID:16415921
PMID:16538176
PMID:16998491
PMID:18370849
PMID:18637831
http://www.fda.gov/.../carbamazepineHCP.htm
-
rs2844682
at chr6:31054127
in
MUC21
This variant is a tagging SNP for HLA-B*1502, which is associated with severe adverse reactions of carbamazepine. Patients carrying the HLA-B*1502 allele have significant higher risk for severe skin reactions (Stevens Johnson syndrome and toxic epidermal necrolysis) associated with carbamazepine therapy.- Variant Name:
- tagging SNP for HLA-B*1502
- Related Drugs:
- carbamazepine, phenytoin
- Related Diseases:
- Bipolar Disorder, Epidermal Necrolysis, Toxic, Epilepsy, Stevens-Johnson Syndrome
- Evidence:
-
PMID:15057820
PMID:16415921
PMID:16538176
PMID:16998491
PMID:18370849
PMID:18637831
http://www.fda.gov/.../carbamazepineHCP.htm
-
rs2032582
at chr7:86998554
in
ABCB1
This variant maybe associated with drug resistance in chinese epilepsy patients. Sample size: 464 chinese epilepsy patients (270 drug responsive, 194 drug resistant).- Variant Name:
- ABCB1: 2677T/A>G
- Related Drugs:
- carbamazepine, clobazam, clonazepam, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, topiramate, valproic acid, vigabatrin
- Related Diseases:
- Epilepsy
- Evidence:
-
PMID:19450124
-
rs3789243
at chr7:87058822
in
ABCB1
This variant maybe associated with drug resistance in chinese epilepsy patients. Sample size: 464 chinese epilepsy patients (270 drug responsive, 194 drug resistant).- Related Drugs:
- carbamazepine, clobazam, clonazepam, gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin, topiramate, valproic acid, vigabatrin
- Related Diseases:
- Epilepsy
- Evidence:
-
PMID:19450124
The following genes are in curated knowledge about this drug.
| Gene | Relationship | Evidence | |
|---|---|---|---|
|
|
ABCB1 |
|
Publications, Variants |
|
|
CYP2B6 |
|
Publications |
|
|
CYP2C19 |
|
Publications |
|
|
CYP2C9 |
|
Publications, Variants |
|
|
CYP2E1 |
|
Publications |
|
|
CYP3A4 |
|
Publications |
|
|
DRD2 |
|
Publications |
|
|
EPHX1 |
|
Publications, Variants |
|
|
FLOT1 |
|
Variants |
|
|
FPGS |
|
Publications |
|
|
HLA-B |
|
Publications |
|
|
MGMT |
|
Publications |
|
|
MUC21 |
|
Variants |
|
|
NR1I2 |
|
Publications |
|
|
NR1I3 |
|
Publications |
|
|
RALBP1 |
|
Publications |
|
|
SCN1A |
|
Publications, Variants |
|
|
SCN1B |
|
Publications |
|
|
SCN2A |
|
Publications, Variants |
|
|
SCN2A2 |
|
Variants |
|
|
UGT1A1 |
|
Publications |
|
|
UGT2B15 |
|
Publications |
A list of non-curated publications that mention this drug along with other genes is available.
Drug Targets
PharmGKB Curated Pathways
The following drugs are in curated knowledge about this drug.
| Drug | Relationship | Evidence | |
|---|---|---|---|
|
|
amitriptyline |
|
Publications |
|
|
capecitabine |
|
Publications |
|
|
clonazepam |
|
Publications |
|
|
donepezil |
|
Publications |
|
|
imipramine |
|
Publications |
|
|
losartan |
|
Publications |
|
|
non-selective monoamine reuptake inhibitors |
|
Publications |
|
|
warfarin |
|
Publications |
A list of non-curated publications that mention this drug along with other drugs is available.
Drug Interactions
| Drug | Description | |
|---|---|---|
| acenocoumarol |
|
Increased hydantoin levels and risk of bleeding (source: Drug Bank) |
| alprazolam |
|
Possible increased levels of the hydantoin, decrease of benzodiazepine (source: Drug Bank) |
| aminophylline |
|
Decreased effect of both products (source: Drug Bank) |
| amiodarone |
|
Amiodarone increases the effect of hydantoin (source: Drug Bank) |
| anisindione |
|
Increased hydantoin levels and risk of bleeding (source: Drug Bank) |
| aprepitant |
|
This CYP3A4 inducer decreases the effect of aprepitant (source: Drug Bank) |
| atracurium |
|
Phenytoin decreases the effect of the muscle relaxant (source: Drug Bank) |
| betamethasone |
|
The enzyme inducer decreases the effect of the corticosteroid (source: Drug Bank) |
| bleomycin |
|
The antineoplasic agent decreases the effect of hydantoin (source: Drug Bank) |
| capecitabine |
|
Capecitabine increases the effect of hydantoin (source: Drug Bank) |
| carboplatin |
|
The antineoplasic agent decreases the effect of hydantoin (source: Drug Bank) |
| carmustine |
|
The antineoplasic agent decreases the effect of hydantoin (source: Drug Bank) |
| chloramphenicol |
|
Increases phenytoin, modifies chloramphenicol (source: Drug Bank) |
| chlordiazepoxide |
|
Possible increased levels of the hydantoin, decrease of benzodiazepine (source: Drug Bank) |
| chlorotrianisene |
|
The enzyme inducer decreases the effect of the hormones (source: Drug Bank) |
| chlorpheniramine |
|
The antihistamine increases the effect of hydantoin (source: Drug Bank) |
| cimetidine |
|
Cimetidine increases the effect of hydantoin (source: Drug Bank) |
| ciprofloxacin |
|
Ciprofloxacin decreases the hydantoin effect (source: Drug Bank) |
| cisplatin |
|
The antineoplasic agent decreases the effect of hydantoin (source: Drug Bank) |
| clarithromycin |
|
Clarithromycin increases the effect and toxicity of phenytoin (source: Drug Bank) |
| clomifene |
|
The enzyme inducer decreases the effect of the hormones (source: Drug Bank) |
| clorazepate |
|
Possible increased levels of the hydantoin, decrease of benzodiazepine (source: Drug Bank) |
| clozapine |
|
The hydantoin decreases the effect of clozapine (source: Drug Bank) |
| conjugated estrogens |
|
The enzyme inducer decreases the effect of the hormones (source: Drug Bank) |
| cortisone acetate |
|
The enzyme inducer decreases the effect of the corticosteroid (source: Drug Bank) |
| cyclosporine |
|
The hydantoin decreases the effect of cyclosporine (source: Drug Bank) |
| dasatinib |
|
Decreased levels/efficacy of dasatinib (source: Drug Bank) |
| delavirdine |
|
The anticonvulsant decreases the effect of delavirdine (source: Drug Bank) |
| dexamethasone |
|
The enzyme inducer decreases the effect of the corticosteroid (source: Drug Bank) |
| diazepam |
|
Possible increased levels of the hydantoin, decrease of benzodiazepine (source: Drug Bank) |
| diazoxide |
|
Diazoxide decreases the hydantoin effect (source: Drug Bank) |
| dicumarol |
|
Increased hydantoin levels and risk of bleeding (source: Drug Bank) |
| diethylstilbestrol |
|
The enzyme inducer decreases the effect of the hormones (source: Drug Bank) |
| disopyramide |
|
The hydantoin decreases the effect of disopyramide (source: Drug Bank) |
| disulfiram |
|
Disulfiram increases the effect of phenytoin (source: Drug Bank) |
| dopamine |
|
Risk of severe hypotension (source: Drug Bank) |
| doxacurium |
|
Phenytoin decreases the effect of the muscle relaxant (source: Drug Bank) |
| doxycycline |
|
The anticonvulsant decreases the effect of doxycycline (source: Drug Bank) |
| dyphylline |
|
Decreased effect of both products (source: Drug Bank) |
| estazolam |
|
Possible increased levels of the hydantoin, decrease of benzodiazepine (source: Drug Bank) |
| estradiol |
|
The enzyme inducer decreases the effect of the hormones (source: Drug Bank) |
| estradiol |
|
This product may cause a slight decrease of contraceptive effect (source: Drug Bank) |
| estriol |
|
The enzyme inducer decreases the effect of the hormones (source: Drug Bank) |
| estrone |
|
The enzyme inducer decreases the effect of the hormones (source: Drug Bank) |
| ethinyl estradiol |
|
This product may cause a slight decrease of contraceptive effect (source: Drug Bank) |
| felbamate |
|
Increased phenytoin levels and decreased felbamate levels (source: Drug Bank) |
| felodipine |
|
The hydantoin decreases the effect of felodipine (source: Drug Bank) |
| fluconazole |
|
Fluconazole increases the effect of hydantoin (source: Drug Bank) |
| fludrocortisone |
|
The enzyme inducer decreases the effect of the corticosteroid (source: Drug Bank) |
| fluorouracil |
|
Fluorouracil increases the effect of hydantoin (source: Drug Bank) |
| fluoxetine |
|
Fluoxetine increases the effect of phenytoin (source: Drug Bank) |
| flurazepam |
|
Possible increased levels of the hydantoin, decrease of benzodiazepine (source: Drug Bank) |
| fluvoxamine |
|
Fluvoxamine increases the effect of hydantoin (source: Drug Bank) |
| folic acid |
|
folic acid decreases the levels of hydantoin (source: Drug Bank) |
| furosemide |
|
The hydantoin decreases the effect of furosemide (source: Drug Bank) |
| gabapentin |
|
Gabapentin increases the effect of hydantoin (source: Drug Bank) |
| gallamine triethiodide |
|
Phenytoin decreases the effect of the muscle relaxant (source: Drug Bank) |
| gefitinib |
|
This CYP3A4 inducer may reduce gefitinib plasma concentrations and pharmacological effects (source: Drug Bank) |
| hydrocortisone |
|
The enzyme inducer decreases the effect of the corticosteroid (source: Drug Bank) |
| imatinib |
|
The hydantoin decreases the levels of imatinib (source: Drug Bank) |
| irinotecan |
|
The hydantoin decreases the effect of irinotecan (source: Drug Bank) |
| isoniazid |
|
Isoniazid increases the effect of phenytoin in 20% of patients (source: Drug Bank) |
| itraconazole |
|
Phenytoin decreases the effect of itraconazole (source: Drug Bank) |
| lamotrigine |
|
Phenytoin may reduce levels of lamotrigine (source: Drug Bank) |
| levodopa |
|
The hydantoin decreases the effect of levodopa (source: Drug Bank) |
| levonorgestrel |
|
Phenytoin decreases the contraceptive effect (source: Drug Bank) |
| lopinavir |
|
Levels of both drugs are affected (source: Drug Bank) |
| lorazepam |
|
Possible increased levels of the hydantoin, decrease of benzodiazepine (source: Drug Bank) |
| mebendazole |
|
The hydantoin decreases the efficiency of mebendazole (source: Drug Bank) |
| medroxyprogesterone |
|
The enzyme inducer decreases the effect of the hormones (source: Drug Bank) |
| megestrol |
|
The enzyme inducer decreases the effect of the hormones (source: Drug Bank) |
| mestranol |
|
This product may cause a slight decrease of contraceptive effect (source: Drug Bank) |
| methotrexate |
|
The antineoplasic agent decreases the effect of hydantoin (source: Drug Bank) |
| methoxsalen |
|
The hydantoin decreases the effect of psoralene (source: Drug Bank) |
| methylprednisolone |
|
The enzyme inducer decreases the effect of the corticosteroid (source: Drug Bank) |
| metocurine |
|
Phenytoin decreases the effect of the muscle relaxant (source: Drug Bank) |
| metyrapone |
|
The combination renders the test invalid (source: Drug Bank) |
| mexiletine |
|
The hydantoin decreases the effect of mexiletine (source: Drug Bank) |
| midazolam |
|
Possible increased levels of the hydantoin, decrease of benzodiazepine (source: Drug Bank) |
| mirtazapine |
|
The hydantoins may reduce mirtazapine plasma concentrations and pharmacological effects (source: Drug Bank) |
| mivacurium |
|
Phenytoin decreases the effect of the muscle relaxant (source: Drug Bank) |
| nisoldipine |
|
Phenytoin decreases the efficiency of nisoldipine (source: Drug Bank) |
| norethindrone |
|
This product may cause a slight decrease of contraceptive effect (source: Drug Bank) |
| omeprazole |
|
Omeprazole increases the effect of hydantoin (source: Drug Bank) |
| oxazepam |
|
Possible increased levels of the hydantoin, decrease of benzodiazepine (source: Drug Bank) |
| oxcarbazepine |
|
Oxcarbazepine increases the effect of hydantoin (source: Drug Bank) |
| oxtriphylline |
|
Decreased effect of both products (source: Drug Bank) |
| oxyphenbutazone |
|
The NSAID increases the effect of hydantoin (source: Drug Bank) |
| pancuronium |
|
Phenytoin decreases the effect of the muscle relaxant (source: Drug Bank) |
| paramethasone |
|
The enzyme inducer decreases the effect of the corticosteroid (source: Drug Bank) |
| phenylbutazone |
|
The NSAID increases the effect of hydantoin (source: Drug Bank) |
| posaconazole |
|
Modifications of drug levels for both agents (source: Drug Bank) |
| praziquantel |
|
Markedly lower praziquantel levels (source: Drug Bank) |
| prednisolone |
|
The enzyme inducer decreases the effect of the corticosteroid (source: Drug Bank) |
| prednisone |
|
The enzyme inducer decreases the effect of the corticosteroid (source: Drug Bank) |
| quazepam |
|
Possible increased levels of the hydantoin, decrease of benzodiazepine (source: Drug Bank) |
| quetiapine |
|
Phenytoin decreases the effect of quetiapine (source: Drug Bank) |
| quinestrol |
|
The enzyme inducer decreases the effect of the hormones (source: Drug Bank) |
| quinidine |
|
The anticonvulsant decreases the effect of quinidine (source: Drug Bank) |
| rifampin |
|
Rifampin decreases the effect of hydantoin (source: Drug Bank) |
| sertraline |
|
Sertraline increases the effect of hydantoin (source: Drug Bank) |
| sirolimus |
|
The hydantoin decreases sirolimus levels (source: Drug Bank) |
| sodium |
|
Valproate increases the effect of hydantoin (source: Drug Bank) |
| sucralfate |
|
Sucralfate decreases the effect of hydantoin (source: Drug Bank) |
| sulfadiazine |
|
The sulfonamide increases the effect of hydantoin (source: Drug Bank) |
| sulfamethizole |
|
The sulfonamide increases the effect of hydantoin (source: Drug Bank) |
| sunitinib |
|
Possible decrease in sunitinib levels (source: Drug Bank) |
| tacrolimus |
|
The hydantoin decreases the effect of tacrolimus (source: Drug Bank) |
| telithromycin |
|
Telithromycin may possibly increase the agent effect/toxicity (source: Drug Bank) |
| temazepam |
|
Possible increased levels of the hydantoin, decrease of benzodiazepine (source: Drug Bank) |
| theophylline |
|
Decreased effect of both products (source: Drug Bank) |
| thiotepa |
|
Possible increase in thiotepa levels (source: Drug Bank) |
| ticlopidine |
|
Ticlopidine increases the effect of hydantoin (source: Drug Bank) |
| topiramate |
|
Increased phenytoin/decreased topiramate (source: Drug Bank) |
| triamcinolone |
|
The enzyme inducer decreases the effect of the corticosteroid (source: Drug Bank) |
| triazolam |
|
Possible increased levels of the hydantoin, decrease of benzodiazepine (source: Drug Bank) |
| trimethoprim |
|
Trimethoprim increases the effect of hydantoin (source: Drug Bank) |
| trioxsalen |
|
The hydantoin decreases the effect of psoralene (source: Drug Bank) |
| tubocurarine |
|
Phenytoin decreases the effect of the muscle relaxant (source: Drug Bank) |
| vecuronium |
|
Phenytoin decreases the effect of the muscle relaxant (source: Drug Bank) |
| vigabatrin |
|
Vigabatrin decreases the effect of hydantoin (source: Drug Bank) |
| vinblastine |
|
The antineoplasic agent decreases the effect of hydantoin (source: Drug Bank) |
| voriconazole |
|
The hydantoin decreases the effect of voriconazole (source: Drug Bank) |
| warfarin |
|
Increased hydantoin levels and risk of bleeding (source: Drug Bank) |
Curated Information
The following diseases are in curated knowledge about this drug.
| Disease | Relationship | Evidence | |
|---|---|---|---|
|
|
Breast Neoplasms |
|
Publications |
|
|
Craniofacial Abnormalities |
|
Publications |
|
|
Drug Hypersensitivity |
|
Publications |
|
|
Drug Toxicity |
|
Publications |
|
|
Epidermal Necrolysis, Toxic |
|
Publications |
|
|
Epilepsy |
|
Publications, Variants |
|
|
Glioblastoma |
|
Publications |
|
|
HIV |
|
Publications |
|
|
Leukemia |
|
Publications |
|
|
Stevens-Johnson Syndrome |
|
Publications |
Non-Curated Information
A list of non-curated publications that mention this drug along with other diseases is available.
Curated Phenotype Datasets
These datasets are sorted alphabetically by title.
- mRNA expression levels of PXR splice variants in livers




- FA
Submitted by Erin G. Schuetz, PhD involving CYP3A4, NR1I2, , amiodarone, cimetidine, dopamine, erythromycin, ethanol, glucocorticoids, hmg coa reductase inhibitors, midazolam, nicotine, phenobarbital, phenytoin, propofol, thyroid preparations and vasopressin
Additional Datasets
These datasets are minimally curated and are sorted alphabetically by title.
Downloads
You must sign in before you can download data.
LinkOuts
Common Searches
Search PubMed
Search Medline Plus
Search PubChem
Search CTD
Non-Curated Publications
A list of non-curated publications that mention this drug is available.
